BioArctic & Mesenkia Team Up to Target Glioblastoma with BBB‑Shuttling Antibody Technology
BioArctic partners with Mesenkia to create a BBB‑shuttled antibody targeting glioblastoma, merging BrainTransporter™ and KITAIbodies® to tackle brain cancer’s toughest barrier.
3 minutes to read